DexaSite (dexamethasone 0.1% in DuraSite) / Sun Pharma - LARVOL DELTA

What can we achieve with novel mass spectrometry techniques (Multiple Myeloma Hub) - "In this video, Mateos discusses the GEM2012MENOS65 trial (NCT01916252), a PETHEMA study, which involved newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide, and dexamethasone (VRD) followed by autologous stem cell transplantation (auto-SCT) and consolidation with VRD."

Video

Addition of Elotuzumab Prolongs Survival in Relapsed or Refractory Myeloma - P3, N=761; ELOQUENT - 2 (NCT01239797); Sponsor: Bristol-Myers Squibb; "Treatment with elotuzumab plus lenalidomide and dexamethasone (ERd) was associated with significant and clinically meaningful reductions in mortality risk, compared with lenalidomide and dexamethasone alone (Rd), in patients with relapsed or refractory multiple myeloma (MM), according to results from the phase III ELOQUENT-2 trial. The survival benefit was particularly evident in older patients and patients with high-risk disease, lead author Meletios Dimopoulos, MD...told ASH Clinical News. 'At the time of study design, Rd was the standard of care for patients with relapsed or refractory MM,' Dr. Dimopoulos said. 'The ERd triplet not only showed a long-standing improvement in progression-free survival [PFS], but also in overall survival [OS].'"

Media quote • P3 data

Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects (clinicaltrials.gov) - P3; N=558; Completed; Sponsor: InSite Vision; Active, not recruiting ➔ Completed; Trial completion date: Sep 2020 ➔ Feb 2020

Clinical • Trial completion • Trial completion date • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Independent Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery (clinicaltrials.gov) - P3; N=246; Completed; Sponsor: InSite Vision; Active, not recruiting ➔ Completed; Trial completion date: Jun 2020 ➔ Nov 2019

Clinical • Trial completion • Trial completion date • Cataract • Immunology • Ocular Inflammation • Ophthalmology • Pain

Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery (clinicaltrials.gov) - P3; N=240; Not yet recruiting; Sponsor: InSite Vision; Initiation date: Aug 2017 ➔ Nov 2017; Trial primary completion date: Apr 2018 ➔ Jul 2018

Trial initiation date • Trial primary completion date • Biosimilar • CNS Disorders • Immunology • Ocular Inflammation • Ophthalmology • Pain

Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects (clinicaltrials.gov) - P3; N=558; Active, not recruiting; Sponsor: InSite Vision; Trial completion date: Apr 2020 ➔ Aug 2020

Clinical • Trial completion date

Independent Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery (clinicaltrials.gov) - P3; N=246; Active, not recruiting; Sponsor: InSite Vision; Trial completion date: Mar 2020 ➔ Jun 2020

Clinical • Trial completion date

Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects (clinicaltrials.gov) - P3; N=558; Active, not recruiting; Sponsor: InSite Vision; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery (clinicaltrials.gov) - P3; N=260; Completed; Sponsor: InSite Vision; Active, not recruiting ➔ Completed

Clinical • Trial completion

Independent Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery (clinicaltrials.gov) - P3; N=240; Active, not recruiting; Sponsor: InSite Vision; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Independent Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery (clinicaltrials.gov) - P3; N=240; Recruiting; Sponsor: InSite Vision; Trial completion date: Dec 2019 ➔ Mar 2020; Trial primary completion date: Sep 2019 ➔ Dec 2019

Clinical • Trial completion date • Trial primary completion date

Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery (clinicaltrials.gov) - P3; N=240; Active, not recruiting; Sponsor: InSite Vision; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects (clinicaltrials.gov) - P3; N=550; Recruiting; Sponsor: InSite Vision; Trial completion date: Aug 2019 ➔ Dec 2019; Trial primary completion date: Apr 2019 ➔ Oct 2019

Clinical • Trial completion date • Trial primary completion date

Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery (clinicaltrials.gov) - P3; N=240; Recruiting; Sponsor: InSite Vision; Trial completion date: Feb 2019 ➔ Aug 2019; Trial primary completion date: Nov 2018 ➔ May 2019

Clinical • Trial completion date • Trial primary completion date

Independent Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery (clinicaltrials.gov) - P3; N=240; Recruiting; Sponsor: InSite Vision; Trial completion date: Feb 2019 ➔ Oct 2019; Trial primary completion date: Nov 2018 ➔ Jul 2019

Clinical • Trial completion date • Trial primary completion date